{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:04:50Z","timestamp":1760101490631,"version":"3.27.0"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,10,15]]},"DOI":"10.2169\/internalmedicine.3325-23","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T22:17:36Z","timestamp":1709504256000},"page":"2767-2771","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic Value of sLR11 and sIL-2R in the Cerebrospinal Fluid for Malignant Central Nervous System Lymphoma"],"prefix":"10.2169","volume":"63","author":[{"given":"Naomi","family":"Shimizu","sequence":"first","affiliation":[{"name":"Department of Hematology, Toho University Sakura Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanshiro","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toho University Sakura Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Hasunuma","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Toho University Sakura Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Hematology, International University of Health and Welfare School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomo","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Tsukuba Research Institute, Sekisui Medical Co. Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ebinuma","sequence":"additional","affiliation":[{"name":"Tsukuba Research Institute, Sekisui Medical Co. Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Bujo","sequence":"additional","affiliation":[{"name":"Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results anaysis. Cancer 95: 1504-1510, 2002.","DOI":"10.1002\/cncr.10851"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ohwaki K, Bujo H, Jiang M, Yamazaki H, Schneider WJ, Saito Y. A secreted soluble form of LR11, specifically expressed in intimal smooth muscle cells, accelerates formation of lipid-laden macrophages. Arterioscler Thromb Vasc Biol 27: 1050-1056, 2007.","DOI":"10.1161\/ATVBAHA.106.137091"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jiang M, Bujo H, Ohwaki K, et al. Ang II-stimulated migration of vascular smooth muscle cells is dependent on LR11 in mice. J Clin Invest 118: 2733-2746, 2008.","DOI":"10.1172\/JCI32381"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Matsuo M, Ebinuma H, Fukamachi I, Jiang M, Bujo H, Saito Y. Development of an immunoassay for the quantification of soluble LR11, a circulating marker of atherosclerosis. Clin Chem 55: 1801-1808, 2009.","DOI":"10.1373\/clinchem.2009.127027"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Takahashi M, Bujo H, Jiang M, Noike H, Saito Y, Shirai K. Enhanced circulating soluble LR11 in patients with coronary organic stenosis. Atherosclerosis 210: 581-584, 2010.","DOI":"10.1016\/j.atherosclerosis.2009.12.010"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sakai S, Nakaseko C, Takeuchi M, et al. Circulating soluble LR11\/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clin Chim Acta 413: 1542-1548, 2012.","DOI":"10.1016\/j.cca.2012.06.025"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sugita Y, Ohwada C, Kawaguchi T, et al. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: a multicenter prospective analysis. Clin Chim Acta 463: 47-52, 2016.","DOI":"10.1016\/j.cca.2016.10.008"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shirouchi Y, Nishimura N, Mishima Y, et al. Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy. Sci Rep 13: 13713, 2023.","DOI":"10.1038\/s41598-023-40026-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ohwada C, Yamazaki A, Kawaguchi T, et al. Serum soluble LR11, a novel tumor derived biomarker associated with the outcome of patients with diffuse large B-cell lymphoma. Leuk Lymphoma 56: 2982-2985, 2015.","DOI":"10.3109\/10428194.2015.1016930"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gregory G, Arumugaswamy A, Leung T, et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol 15: 1068-1073, 2013.","DOI":"10.1093\/neuonc\/not032"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 83: 235-239, 2014.","DOI":"10.1212\/WNL.0000000000000593"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with Methotrexate, cytarabine, thiotepa, and rituximab (MATRIX regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) Phase 2 Trial. Lancet Haematol 3: e217-e227, 2016.","DOI":"10.1016\/S2352-3026(16)00036-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ikeuchi T, Hirayama S, Miida T, et al. Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease. Dement Geriatr Cogn Disord 30: 28-32, 2010.","DOI":"10.1159\/000315539"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sasagawa Y, Akai T, Tachibana O, Iizuka H. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. J Neurooncol 121: 177-183, 2015.","DOI":"10.1007\/s11060-014-1622-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Maeyama M, Sasayama T, Tanaka K, et al. Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and \u03b22-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma. Cancer Med 9: 4114-4125, 2020.","DOI":"10.1002\/cam4.3048"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/20\/63_3325-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T03:28:20Z","timestamp":1729308500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/20\/63_3325-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":15,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3325-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"article-number":"3325-23"}}